Inclusion Criteria:

          1. Females ≥18 years of age

          2. Platinum-resistant recurrent or metastatic epithelial ovarian carcinoma

          3. Positivity on CD44 assay as defined by strong (+++) or moderate (++) staining in 20%
             or more of the tumor tissue/stroma as obtained by biopsy or paracentesis

          4. Status post first-line therapy with definitive surgery (which provided tissue for
             pathologic diagnosis) and chemotherapy

          5. Original diagnosis has been confirmed through a histopathologic review of the primary
             tumor slides by an expert pathologist at the Principal Investigator's institution

          6. Disease has progressed or recurred during or less than 6 months after platinum-based
             chemotherapy at some point during the subject's course.

          7. No more than 3 prior regimens of cytotoxic chemotherapy unless approved by the sponsor
             (Note: all platinum-containing regimens are not to be counted separately but are
             considered to be a single regimen for the purposes of this criterion)

          8. Measurable disease by RECIST 1.1 criteria

          9. Eastern Cooperative Oncology Group performance status (ECOG PS) of 0, 1, or 2

         10. Women with childbearing potential and partners must both use effective contraception
             during the study and for 3 months after the last dose

         11. Life expectancy of at least 6 months

         12. Able to understand and comply with the study procedures, understand the risks involved
             in the study, and provide written informed consent before the first study-specific
             procedure

        Exclusion Criteria:

          1. Treatment with cytotoxic chemotherapy for malignancies other than ovarian cancer
             within the past 5 years

          2. Fewer than 28 days before Cycle 1 Day 1 since any prior chemotherapy (less than 42
             days in the case of mitomycin or a nitrosourea)

          3. Fewer than 28 days before Cycle 1 Day 1 since administration of hormonal or biological
             anti-neoplastic agents

          4. Concomitant use of other cytotoxic or cytostatic drugs other than PTX

          5. Abnormal clinical laboratory values within 14 days prior to initiation of dosing, as
             indicated by:

               -  Hemoglobin level <9.0 gm/L

               -  Platelet count <100,000/mm3

               -  Granulocyte count <1500/mm3

               -  Serum creatinine level ≥2.5 mg/dL (221 μmol/L)

               -  Liver aminotransferase levels greater than 3 times the laboratory's upper limit
                  of normal (greater than 5 times the laboratory's upper limit of normal if the
                  liver is known to be involved with tumor)

          6. Contraindication to the use of PTX

          7. Pregnancy or breast-feeding at time of Screening and throughout the study.

          8. Active, uncontrolled infection

          9. Participation in another investigational drug trial concurrently or within 30 days of
             Cycle 1 Day 1, or a vaccine trial within 90 days of Cycle 1 Day 1

         10. Significant acute or chronic medical or psychiatric illness that, in the judgment of
             the Investigator, could compromise subject safety, limit the subject's ability to
             complete the trial, and/or compromise the objectives of the trial